The Canadian Institutes of Health Research (CIHR) or Compugen Ltd. (CGEn) has announced the HostSeq Postdoctoral Fellowships program for the academic year 2022/2023.
The CGEn HostSeq/CIHR Joint Postdoctoral Fellowship Program will support highly-qualified postdoctoral trainees whose research involves the study of human genetics and the challenges of COVID-19 disease in Canada using bioinformatic approaches. Successful applicants to the fellowship program must apply for access to and use CGEn’s host genome sequencing (HostSeq) Databank to support their postdoctoral research project.
- Award
- Application Process
- Clarity of Information
Summary
Amazing opportunity to get financial assistance in Canada or Israel.The Canadian Institutes of Health Research is the principal federal agency responsible for funding health and medical research in Canada. It is the successor to the Medical Research Council of Canada. It aims to create new health knowledge and translate that knowledge from the research setting into real-world applications. CIHR supports more than 13,000 researchers and trainees as part of the federal government’s investment in health research. Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and Development Company headquartered in Israel. Compugen was established as a computational drug discovery service provider in 1993. It had arrangements with big pharma such as Novartis AG, Abbot Laboratories, and Pfizer Inc.
Why would you like to study at the Canadian Institutes of Health Research (CIHR) or Compugen Ltd. (CGEn)? It is an independent agency accountable to Parliament through the Minister of Health. Their mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened Canadian health care system. Compugen is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platform to identify novel drug targets and new biological pathways and develop therapeutics in cancer immunotherapy.